Impact of Age on Clinical Outcomes Following Left Atrial Appendage Occlusion: A Meta-Analysis And Systematic Review

Amro Alseid1, Ibrahim O Abunemr2, Rakesh Prashad3

  • 1Internal Medicine, University of Central Florida College of Medicine, Ocala, USA.

Cureus
|January 8, 2026
PubMed

Left atrial appendage occlusion (LAAO) offers an alternative to oral anticoagulation for stroke prevention in patients with non-valvular atrial fibrillation; however, the impact of advanced age on outcomes remains uncertain. We conducted a systematic review and meta-analysis to evaluate the effect of age on in-hospital and long-term outcomes following LAAO. A comprehensive search of PubMed and Google Scholar yielded 1,372 studies, of which seven met the inclusion criteria after screening and full-text review. Eligible studies stratified outcomes by age (<75 vs ≥75, <80 vs ≥80, or multilevel age groups), and we analyzed all-cause mortality, stroke/systemic embolism (SE), and major bleeding using relative risks (RRs) with 95% confidence intervals (CI). Long-term mortality was significantly higher among older patients, with mortality rising from 32.4% at age 65-69 to 63.4% in those ≥85 (RR 1.96, 95%CI 1.90-2.03), and from 14.3% <80 to 38.8% ≥80 (RR 2.71, 95%CI 2.24-3.28). Pooled analysis demonstrated substantial heterogeneity for mortality (I² = 80.7%). Stroke/SE rates were modestly elevated with age, including 13.0% in ≥85 vs 5.3% at 65-69 (RR 2.45, 95%CI 2.00-3.00), with moderate heterogeneity across studies (I² = 63.9%). Major bleeding consistently increased in older groups, such as 18.4% ≥85 vs 12.0% at 65-69 (RR 1.53, 95%CI 1.35-1.72) and 22.6% ≥80 vs 12.1% <80 (RR 1.87, 95%CI 1.44-2.41), with high heterogeneity (I² = 83.4%). In-hospital mortality and stroke/SE were low overall but showed age-related increases in large cohorts. A funnel plot suggested no major publication bias. LAAO provides consistent stroke prevention across all ages, but older patients, particularly those ≥80-experience significantly higher mortality and bleeding risks. Age should not contraindicate LAAO but should guide individualized risk-benefit discussions, especially regarding bleeding management and long-term prognosis.

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
207
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
183
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
239
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
347
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
406
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
388